Clinical Genomics Appoints New CEO

On Jan 4, 2019

Clinical Genomics, a leading provider of cancer diagnostic solutions including liquid biopsy tests, announced the appointment of Betsy Hanna as president and chief executive officer. Hanna will also join the Clinical Genomics Board of Directors.

Hanna succeeds Dr. Lawrence LaPointe as CEO, who after a decade building Clinical Genomics will transition to the new role of chief innovation officer, responsible for developing solutions to improve healthcare leading clinical trials, R&D and scientific developments. He will continue to serve as an advisor to the board.

The appointments are effective immediately.

Clinical Genomics’ board chairman Mary Padbury noted, “Both Betsy and Larry bring enormous experience in their new roles. Betsy was most recently our chief commercial officer and has a 20-year career in healthcare turning products into commercial successes. Larry, as a co-founder and an accomplished scientist, will continue to lead our innovation in this rapidly evolving field.”

Ms. Hanna noted, “Clinical Genomics has been successful in science and product development. Our challenge now is to accelerate commercial growth with COLVERA, a blood diagnostic for colorectal cancer (CRC) recurrence, and InSure^®ONE™, both now in the market. Our goal is to also expand future applications in screening.”

To access more business news, visit NJB News Now.

Related Articles: